- About Us
- Clinical Trials
Available Clinical Trials
- Resources
- Contact Us
A Randomized Phase II Study of Ruxolitinib (NSC-752295) in Combination with BCR-ABL Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia (CML) Patients with Molecular Evidence of Disease
S1712 is permanently closed to accrual, effective October 20, 2022.